Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Denali Therapeutics (DNLI) EBT Margin (2018 - 2023)

Historic EBT Margin for Denali Therapeutics (DNLI) over the last 6 years, with Q3 2023 value amounting to 7841.59%.

  • Denali Therapeutics' EBT Margin fell 49391200.0% to 7841.59% in Q3 2023 from the same period last year, while for Jun 2024 it was 33119.49%, marking a year-over-year decrease of 330820800.0%. This contributed to the annual value of 43.93% for FY2023, which is 2566100.0% up from last year.
  • Latest data reveals that Denali Therapeutics reported EBT Margin of 7841.59% as of Q3 2023, which was down 49391200.0% from 62.35% recorded in Q2 2023.
  • Denali Therapeutics' 5-year EBT Margin high stood at 77.56% for Q4 2020, and its period low was 7841.59% during Q3 2023.
  • Moreover, its 5-year median value for EBT Margin was 884.02% (2021), whereas its average is 1192.8%.
  • In the last 5 years, Denali Therapeutics' EBT Margin surged by 30895700bps in 2019 and then tumbled by -49391200bps in 2023.
  • Denali Therapeutics' EBT Margin (Quarter) stood at 1154.75% in 2019, then surged by 107bps to 77.56% in 2020, then crashed by -881bps to 606.01% in 2021, then plummeted by -58bps to 959.68% in 2022, then tumbled by -717bps to 7841.59% in 2023.
  • Its EBT Margin stands at 7841.59% for Q3 2023, versus 62.35% for Q2 2023 and 312.4% for Q1 2023.